Literature DB >> 2002511

Development and utilization of physiologically based pharmacokinetic models for toxicological applications.

H W Leung1.   

Abstract

Recent advances in physiologically based pharmacokinetic (PB-PK) modeling have introduced novel approaches for evaluating toxicological problems. Because PB-PK models are amenable to extrapolation of tissue dosimetry, they are increasingly being applied to chemical risk assessment. This paper reviews the development of PB-PK modeling for toxicological applications. It briefly compares and contrasts the fundamental differences between conventional compartmental analysis and PB-PK modeling. The theory and principles, data requirements and the methodologies to obtain them, and the steps to construct PB-PK models are described. A comprehensive listing of PB-PK models for environmental chemicals developed to date is referenced. Salient applications of PB-PK modeling to toxicological problems are illustrated with examples. Finally, the uncertainties and limitations in PB-PK modeling are also discussed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2002511     DOI: 10.1080/15287399109531480

Source DB:  PubMed          Journal:  J Toxicol Environ Health        ISSN: 0098-4108


  15 in total

1.  From piecewise to full physiologic pharmacokinetic modeling: applied to thiopental disposition in the rat.

Authors:  W F Ebling; D R Wada; D R Stanski
Journal:  J Pharmacokinet Biopharm       Date:  1994-08

Review 2.  Perspectives in pharmacokinetics. Physiologically based pharmacokinetic modeling as a tool for drug development.

Authors:  S B Charnick; R Kawai; J R Nedelman; M Lemaire; W Niederberger; H Sato
Journal:  J Pharmacokinet Biopharm       Date:  1995-04

3.  Effect of various exposure scenarios on the biological monitoring of organic solvents in alveolar air. I. Toluene and m-xylene.

Authors:  S Laparé; R Tardif; J Brodeur
Journal:  Int Arch Occup Environ Health       Date:  1993       Impact factor: 3.015

4.  A physiologically based pharmacokinetic model for nicotine and cotinine in man.

Authors:  D E Robinson; N J Balter; S L Schwartz
Journal:  J Pharmacokinet Biopharm       Date:  1992-12

5.  IMPROVED TRANSFORMATION OF MORPHOMETRIC MEASUREMENTS FOR A PRIORI PARAMETER ESTIMATION IN A PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODEL OF ETHANOL.

Authors:  Martin H Plawecki; Ray Decarlo; Vijay A Ramchandani; Sean O'Connor
Journal:  Biomed Signal Process Control       Date:  2007-04       Impact factor: 3.880

6.  Effect of various exposure scenarios on the biological monitoring of organic solvents in alveolar air. II. 1,1,1-Trichloroethane and trichloroethylene.

Authors:  S Laparé; R Tardif; J Brodeur
Journal:  Int Arch Occup Environ Health       Date:  1995       Impact factor: 3.015

Review 7.  Physiologically based pharmacokinetic models: integration of in silico approaches with micro cell culture analogues.

Authors:  A Chen; M L Yarmush; T Maguire
Journal:  Curr Drug Metab       Date:  2012-07       Impact factor: 3.731

8.  Physiologically based pharmacokinetics and cancer risk assessment.

Authors:  M E Andersen; K Krishnan
Journal:  Environ Health Perspect       Date:  1994-01       Impact factor: 9.031

9.  Three-dimensional visualization of physiologically based kinetic model outputs.

Authors:  J Nichols; P Rheingans; D Lothenbach; R McGeachie; L Skow; J McKim
Journal:  Environ Health Perspect       Date:  1994-11       Impact factor: 9.031

10.  Physiologically based toxicokinetic modeling of 1,3-butadiene lung metabolism in mice becomes more important at low doses.

Authors:  C T Evelo; J G Oostendorp; W F ten Berge; P J Borm
Journal:  Environ Health Perspect       Date:  1993-11       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.